http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102343240-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102343240-B1 |
titleOfInvention | Biomarker composition for predicition of cetuximab treatment effects in colorectal cancer |
abstract | Disclosed herein is the surrogate biomarker CXCL1/5 for the KRAS/BRAF mutation. CXCL1/5 detection according to the present application can monitor the treatment effect by pre-determining whether or not resistance to a colorectal cancer target anticancer agent is present using a blood sample without a biopsy for colorectal cancer, and present a more effective personalized treatment strategy It can ultimately contribute greatly to the improvement of colorectal cancer treatment. |
priorityDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 738.